Evaluation of Cisplatin in Combination with a Biologic Response Modifier in a Murine Mammary Carcinoma Model

• Published in: Cancer investigation Vol. 20; no. 4; pp. 480 - 489
• Main Authors: Morello, Emanuela, Dernell, William S., Kuntz, Charles A., LaRue, Susan M., Lafferty, Mary, Nelson, Ann, Brekke, John H., Mallinckrodt, Craig H., Withrow, Stephen J., Manning, Mark C.
• Format: Journal Article
• Language: English
• Published: New York, NY Informa UK Ltd 2002; Taylor & Francis; Informa Healthcare
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adjuvants, Immunologic - therapeutic use; Animals; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Bile; Biological and medical sciences; Carcinoma; Cisplatin; Cisplatin - therapeutic use; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Controlled release; Delayed-Action Preparations; Drug Therapy, Combination; Female; Immunologic Factors - therapeutic use; Injections, Intraperitoneal; Lactic Acid; Mammary Neoplasms, Experimental - drug therapy; Mammary Neoplasms, Experimental - mortality; Mammary Neoplasms, Experimental - pathology; Medical sciences; Mice; Mice, Inbred C3H; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Pharmacology. Drug treatments; Polyesters; Polymers; Survival Rate; Tissue Extracts; Virulizin; Antineoplastic agent; Potentiation; Recurrence; Carcinoma; Biological response modifier; Toxicity; Drug carrier; Metastasis; Intracavitary administration; Immunotherapy; Mammary gland; Platinum II Complexes; Immunostimulation; Control release polymer; Treatment efficiency; Rodentia; Intratumoral administration; Antimetastatic agent; Malignant tumor; Cisplatin; Mammary gland diseases; Vertebrata; Chemotherapy; Lactic acid polymer; Mammalia; Treatment; Mouse; Animal; Dosage form; Combined treatment; Comparative study
• ISSN: 0735-7907; 1532-4192
• DOI: 10.1081/CNV-120002148

The purpose of this study was to determine the efficacy of intracavitary cisplatin against local regrowth and metastasis after resection of a murine mammary carcinoma and the ability of a biologic response modifier (Virulizin®) to enhance chemotherapy. C3H-HeJ mice were injected with Gollin-B tumor cells. Once growth reached 8 mm, tumors underwent marginal resection and the mice were assigned randomly to intraperitoneal (IP) cisplatin, Virulizin, a controlled release cisplatin-impregnated sponge (OPLA-Pt), a combination of treatments or no treatment and were evaluated for local regrowth, metastasis, and toxicity at 14 or 60 days after surgery.
A possible beneficial interaction was seen between OPLA-Pt and Virulizin at 14 days. All cisplatin groups had significant advantages over controls in all variables measured with OPLA-Pt displaying significant advantages over IP cisplatin in local recurrence rate, tumor score, survival time, and delay in regrowth at 60 days. No toxicity related to either cisplatin or Virulizin was observed.